MAPT and Alzheimer disease: Two forms of active MG with antagonistic actions have been identified: MG-M1 (pro-inflammatory) and MG-M2 (anti-inflammatory); the MG-M1 form is prevalent in AD, leading to Aβ and tau accumulations, neuronal damage, and synaptic dysfunction [162].